Sarcomas/TGCT | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Randall on Initial Considerations When Treating Patients With Desmoid Tumors

October 26th 2021

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

Annamycin Showcases Early Clinical Activity in Soft Tissue Sarcoma Lung Metastases

October 26th 2021

Treatment with the next-generation anthracycline annamycin was found to result in preliminary clinical activity without dose-limiting toxicities in patients with soft tissue sarcoma lung metastases.

Risk-Stratification Can Be Used to Prevent Overtreatment in Children, AYA Patients With Synovial Sarcoma

October 25th 2021

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Dr. Van Tine on Next Steps With Catequentinib in Soft Tissue Sarcoma

October 14th 2021

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.

PROMIS Scores Provide Insight Into PROs With Radiation Therapy in Soft Tissue Sarcoma

October 14th 2021

Patient Reported Outcomes Measurement Information System scoring indicated that preoperative and postoperative radiation therapy was associated with worse anxiety and physical function in patients with soft tissue sarcoma who had resulting wound complications compared with those who did not.

Retroperitoneal Surgical Resection Requires Multipronged Decision Making in Sarcoma

October 8th 2021

Retroperitoneal surgery for patients with sarcoma requires nuanced decision making that incorporates technical aspects of resection, as well as patient-related and tumor-related factors, according to a presentation given during the 2021 ESMO Congress.

Vimseltinib Demonstrates Encouraging Preliminary Efficacy, Tolerability in TGCT

October 6th 2021

Vimseltinib was well tolerated and demonstrated promising preliminary efficacy in patients with tenosynovial giant cell tumors whose tumors are not amendable to surgical resection, according to results from a phase 1/2 study.

Dr. Nassif on the Efficacy of Early-Phase Clinical Trials in Soft Tissue Sarcoma

October 4th 2021

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Treatment Should Not Be Dependent on Age in Soft Tissue Sarcoma

October 4th 2021

Soft tissue sarcoma was the primary cause of death in patients over the age of 75 years, indicating that age alone should not be a prohibitive factor for treatment in older patients, according to findings from a retrospective analysis that was presented at the 2021 ESMO Congress.

Catequentinib Proves Efficacious, Well Tolerated in Synovial Sarcoma

October 1st 2021

Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.

Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi Sarcoma

September 27th 2021

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Durvalumab Plus Olaparib or Cediranib Leads to Disease Stabilization in Leiomyosarcoma

September 23rd 2021

Albiruni Ryan Abdul Razak, discusses the rationale for examining durvalumab with either olaparib or cediranib in patients with LMS, key data reported with this approach, and next steps for the phase 2 DAPPER study.

Challenges Identified With Low Clinical Trial Accrual for AYA Patients With Sarcoma

September 23rd 2021

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

Initial Guideline Development Showcases Future Directions in Ultra-Rare Sarcoma Subtype

September 15th 2021

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma

September 7th 2021

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

ASTRO Guideline Provides Clarity on Radiation Use in Soft Tissue Sarcoma

August 30th 2021

The American Society for Radiation Oncology released a new clinical guideline, which was also published in Practical Radiation Oncology, outlined recommendations and patient selection for optimal radiation dosing, sequencing, and treatment planning for patients with soft tissue sarcoma.

Population-Based Data Show Amputations in Malignant Foot Neoplasms Correlate With Hispanics, Males

August 24th 2021

Amputations were found to be associated with Hispanic ethnicity and male sex in patients with neoplasms of the foot.

Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

August 24th 2021

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Avapritinib Does Not Show PFS Benefit Over Regorafenib in Late-Line GIST, But Remains Active Option for Select Subset

August 6th 2021

Avapritinib did not improve progression-free survival vs regorafenib in patients with unresectable or metastatic gastrointestinal stromal tumors, but the agent continues to be the most active available option for a subset of patients with PDGFRA D842V–mutant disease.

FDA Grants Orphan Drug Designation to Sotigalimab for Soft Tissue Sarcoma

August 5th 2021

The FDA has granted an orphan drug designation to sotigalimab as a potential therapeutic option for patients with soft tissue sarcoma.